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1. Introduction 
The number of people suffering from dementia might triple over the next 50 years, measures 
for treatment and prevention of dementia are crucial. As vitamins are involved in many 
biochemical processes, they are essential for good health. They can possibly take role more 
probably in the prevention and treatment of dementia.  For this reason, the relations 
between the vitamins and dementia, especially Alzheimer Dementia (AD) have been 
studied for many years.  
Until the 1900s, vitamins were obtained solely through food intake, and changes in diet can 
alter the types and amounts of vitamins ingested. Vitamins have been produced as 
commodity chemicals and made widely available as inexpensive pills for several decades, 
allowing supplementation of dietary intake. 
There are many observational studies indicating associations of vitamin deficiencies with 
cognitive dysfunction. Most of the studies in the subject are cross sectional studies. 
Nevertheless, these type of studies can not prove whether a nutritional deficit is the cause or 
the result of an impaired cognitive status. Longitudinal prospective observational studies 
and interventional studies are more suitable to releave causal relationships. Interventional 
studies with long follow up periods are preferred, since short follow up time can not be 
enough to evaluate the effects.  There are some individual studies reporting promising, 
positive results about vitamin supplementation in prevention and treatment of dementia.  
Vitamin A, C and E have antioxidant activity, which have been investigated for its 
prevention from neuronal death and improving neuronal function through maintaining 
mitochondrial homeostasis. Vitamin E may modulate signal transduction pathways and 
participate in the synthesis pathways of neurotransmitters. Several epidemiological studies 
have indicated a relationship between blood concentrations of antioxidant micronutrients 
and cognitive impairment. Though not sufficient, there are some prospective longitudinal 
and interventional studies indicating the useful effects of antioxidant vitamins in prevention 
and treatment of dementia.  
Deficiencies of several B vitamins, including thiamine (B1), riboflavin (B2), niacin (B3), 
pyridoxine (B6), folate (B9) and cobalamin (B12) have been reported to be associated with 
cognitive dysfunction in many studies. In some studies, pathophysiological models have 
been formulated, including the association of B vitamin deficiencies with metabolic 
disturbances in the structural constituents of cerebral tissue, such as phospholipids and 
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myelin, as well as in signaling molecules, such as neurotransmitters. More recently, the 
association between the deficiency of B vitamins, particularly folate and cobalamin, and 
cognitive impairment has been investigated in relation to hyperhomocysteinemia. It was 
shown that plasma homocysteine is a better correlate of cognitive function than the serum 
folate or cobalamin concentrations themselves. Homocysteine is a well established risk 
factor for vascular disease, but some epidemiological and cross sectional studies have also 
suggested that it may play a role in cognitive performance and pathophysiology of 
dementia in older people, possibly as the metabolic link between micro-vascular disease and 
Alzheimer dementia. Some prospective longitudinal and interventional studies have 
reported the useful effects of some B vitamins, though there existed contradictory results 
also. Furthermore, there was a large heterogenity among present vitamin B interventional 
studies with cognitive assessments in terms of dosage, routes of intervention (for vitamin 
B12), age and cognitive function assessments. It seems that it will be worthwhile to perform 
new larger studies, especially considering the results of the studies reporting recovering 
effect of folate supplementation on cognition. 
The most recent reported vitamins related to cognitive functioning are vitamin D and 
vitamin K. Vitamin D has been reported to be critical to healthy brain development and 
function. Vitamin D in sufficient amounts seemed to protect brain cells and reduce 
inflammation according to some biological evidence. Some epidemiological and cross-
sectional studies showed the association of vitamin D deficiency with Alzheimer disease 
and dementia. To disclose if there is a causal relationship between them, prospective 
longitudinal studies are needed in the subject. Vitamin K is also required for normal brain 
development and function. Some authors proposed a possible role of vitamin K deficiency 
in the pathogenesis of Alzheimer disease. It is obviously useful to do experimental animal 
and case controlled human studies in the first step to clarify the role of vitamin K in the 
pathogenesis of dementia. 
In this section, we will try to discuss the relations of AD with the antioxidant vitamins, B 
vitamins and lastly vitamin D and K with the help of cross-sectional or longitudinal 
prospective observational studies, and interventional studies. Nevertheless, the subject has 
many aspects.  As vitamin deficiencies can cause cognitive impairment, cognitive 
impairment can also determine changes in dietary habits and consequently cause vitamin 
deficiencies. Vitamin intake through food or supplementation forms can have different 
effects. There is also a possibility that vitamins have useful effects in different subgroups of 
people, based on age, nutritional status or vitamin level.  Multivitamin supplementation 
may be more useful. Detailed investigations about these aspects will be informative. 
2. Antioxidant vitamins 
2.1 Pathophysiological mechanisms 
Brain tissue is particularly vulnerable to free-radical damage because of its low level of 
endogenous antioxidants (Reiter, 1995). Neuropathological studies documented typical 
lesions from exposure to free radicals in the brains of patients with AD (Behl, 1997; Christen, 
2000; Pratico & Delanty, 2000; Varadarajan et al., 2000). Lipid peroxidation seems to be 
especially susceptible to oxidative stress (Knopman, 1998; Pitchumoni et al., 1998; Sinclair et 
al., 1998). Increasing evidence also implicates neuronal membrane associated oxidative 
stress (for example, consequent to deposition of amyloid ǃ-peptide (Aǃ)) and alteration of 
membrane lipid metabolism (and consequent accumulation of ceramides and cholesterol) as 
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pathogenetic factors of synaptic dysfunction and neuronal degeneration (Cutler et al., 2004; 
Hyun et al., 2010; L.J. Miller & Chacko, 2004). Antioxidant treatment improved neuronal 
function through maintaining mitochondrial homeostasis. In a canine model of human 
aging, it was shown that aged canine mitochondria showed significant increases in reactive 
oxygen species production and a reduction in NADH-linked respiration. Mitochondrial 
function was improved selectively in aged dogs treated with antioxidant diet (Head et al., 
2009). 
Vitamin A levels in brain decline with age and lower still in individuals with AD 
(Goodman, 2006).A metabolic product of vitamin A, retinoic acid, is known to slow cell 
death and offer protection from Aǃ (Sahin et al., 2005). In addition to its antioxidant activity, 
vitamin E may modulate signal transduction pathways and participate in the synthesis 
pathways of neurotransmitters (Azzi et al., 1992; Martin et al., 1997; Meydani et al., 1997). 
Plasma vitamin C level was decreased in AD in addition to vitamin A and E (Foy et al., 
1999). Vitamin C enhances the effect of medications used to treat dementia allowing the 
drugs to pass more easily into the brain and therefore to cause a greater effect. As a 
conflicting result, in the analysis of the association between the level of serum antioxidants 
and memory performance in an elderly, multiethnic sample of 4809 subjects; Perkins et al 
(Perkins et al., 1999) found a decreased serum level of vitamin E consistently associated with 
memory deficit after adjustment for age, education, income and vascular risk factors. Serum 
levels of other antioxidants (vitamins A and C, ǃ-carotene and selenium) did not correlate 
with memory performance. 
2.2 Studies 
SENECA study reported a positive, although weak, correlation between plasma 
concentrations of lycopene, ǂ- carotene, ǃ-carotene, total carotenes, ǃ-cryptoxanthin, ǂ-
tocopherol and Mini Mental State Examination (MMSE) scores (Haller et al., 1996). In the 
elderly population studied by Ortega et al., dietary intake of vitamin C, ǃ-carotene and 
vitamin E were associated with a better cognitive function (Ortega et al., 2002). Perrig et al. 
(Perrig et al., 1997) showed that higher plasma ascorbic acid and ǃ-carotene concentrations 
were associated with better memory performance in older people, both cross-sectionally and 
longitudinally over a 22 year period. In another cohort study performed on 455 elderly 
people with a duration of 7 year, high ǃ-carotene levels were associated with less cognitive 
decline in APOE4 carriers but not in APOE4 negatives (Hu et al., 2006). Rats given dietary 
supplements of fruit and vegetable extracts for 8 months, beginning at 6 months of age, 
slowed age-related declines in neuronal and cognitive functions (Joseph et al., 1998). More 
importantly, these rats were able to reverse age-related deficits in several neuronal and 
behavioral parameters when administration was started at 19 months of age (Joseph et al., 
1999). In another study investigating the effects of acute, short and long term pre-training 
administration of ascorbic acid on passive avoidance learning and memory in rats, it was 
concluded that short- and long-term supplementation with ascorbic acid (vitamin C) had 
facilitatory effects on acquisition and retrieval processes of passive avoidance learning and 
memory in rats (Shadidi et al., 2008). 
Vitamin C supplements were shown to protect against cognitive decline in a 4 year follow 
up study (Paleologos et al., 1998). In Rotterdam Study (Engelhart et al., 2002), the cohort 
study of dietary antioxidants with a duration of 6 years, high intakes of vitamin C and E  
were found to be associated with lower risk of AD. In a recent study on 5395 participants 
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older than 54 years of age and free of dementia with a mean follow up period of 9.6 years, it 
was shown that participants in the highest tertile of vitamin E intake were 25% less likely to 
develop dementia compared with those in the lowest tertile of the intake. Dietary intake 
levels of vitamin C, beta carotene, and flavonoids were not related with dementia risk after 
multivariate adjustments. Results were similar when risk for AD was specifically assessed 
(Devore et al., 2010). In CHAP cohort study, on 815 elderly residents free of AD at baseline 
with a follow up period of 3.9 years, it was found that dietary vitamin E was associated with 
decreased risk for AD,  while intakes of vitamin C, ǃ-carotene and vitamin E from 
supplements were not associated at all (M.C. Morris et al., 2002). In another study  
investigating the effects of  high dietary intake of vitamin E on prevention from AD, it was 
found that  ǂ-tocopherol alone may not be as protective as the combined tocopherols (M.C. 
Morris et al., 2005a). In addition, the risk of AD was inversely related to the intake of ǂ, Ǆ 
and ǅ but not ǃ tocopherol. It was found that higher levels of dietary vitamin E lowered the 
risk of AD and slowed cognitive decline over the six-year course of the investigation. 
In Cache County study, performed on 3227 subjects older than 64 years of age with a follow-
up period of 3 years, vitamin E and C supplements in combination were associated with 
reduction in AD incidence, but not in users of those supplements alone (Zandii et al., 2004). 
Likewise, in another cohort study with a 5 year follow-up period, conducted on 894 elderly 
subjects, combined use of vitamins E and C supplements were associated with less cognitive 
decline (Maxwell et al., 2005); while in another study performed on 2969 elderly participants 
without cognitive impairment at baseline, the use of supplemental vitamin E and C, alone or 
in combination, did not reduce risk of AD or overall dementia over 5.5 years of follow-up 
period (Gray et al., 2008). In spite of the successful results of dietary intake of vitamin E on 
the prevention, supplemental  use of it alone (2000 IU/day) was not shown to have an effect 
on progression of minimal cognitive impairment to AD and on mean cognitive change in 
randomised controlled studies respectively (Kang et al., 2006; Petersen et al., 2005). In a 
randomised controlled study performed on 341 patients with moderate AD, the patients 
treated with selegiline, ǂ-tocopherol supplement  or combination of them had longer time to 
institutionalization (Sano et al., 1997). However, no significant benefit was shown in 
cognitive tests. 
About the role of vitamin E in treatment, there is a safety problem other than analying its 
effectiveness. Recent meta-analyses of randomized trials involving vitamin E in cardiac 
patients and other patient groups suggest a slightly higher mortality risk associated with 
vitamin E treatment (Bjelokovic et al., 2007; E.R. Miller et al., 2005; Vivekananthan et al., 
2003). One meta -analysis (E.R. Miller, 2005) concluded that the mortality rate associated 
with vitamin E treatment increased in a nonlinear dose-dependent manner, with the 
relative risk beginning to rise above 1 at doses ≥ 400 IU/day. In a study about this subject 
performed on 847 probable or mixed AD patients with a follow up period up to 15 years, 
there was no evidence that treatment with high doses of vitamin E (2000 IU/day)had an 
adverse effect on survival. In fact, patients whose regimens included vitamin E tended to 
survive longer than those taking no drug or a choline esterase inhibitor alone. It is 
noteworthy that the survival benefit to those taking vitamin E did not become apparent 
until after 4 or more years of follow up. In light of the potential for beneficial effects on 
vitamin E and mixed clinical trial evidence, these results emphasize the need for 
additional research on vitamin E supplementation in AD using a dose range that extends 
above 400 IU per day.  
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2.3 Comments 
In conclusion, there are positive results about the use of antioxidant vitamins on mostly 
prevention of AD and mostly through diet. There is not sufficient evidence about their use 
in the treatment. In recent years, it seems that the researches on vitamin E and C have 
dominated. This can be due to the relation of these vitamins to the structure and physiology 
of brain and, more consistent finding of association between serum levels of vitamin E and 
memory performance in the studies.  However, vitamin A is also a good candidate for more 
future studies.  
The intake of vitamins through diet or supplementation forms and the number or quantity 
of different vitamins and presence of other ingredients in the supplementation forms can 
change the effect. For example, in the manufactured capsules of vitamin E, only ǂ-
tocopherol is present. But at real, vitamin E is composed of 4 different tocopherol forms and 
4 corresponding tocotrienols. This may cause ineffectiveness of vitamin E supplementation 
found in some studies. Also, the interaction of antioxidant vitamins with other antioxidants 
like flavonoids and other chemicals present in fruits and vegetables can provide benefit in 
the dietary intake of vitamins. 
3. B vitamins 
3.1 Pathophysiological mechanisms 
Deficiencies of several B vitamins, including thiamine (B1), riboflavin (B2), niasin (B3), 
pyridoxine (B6), folate (B9) and cobalamin (B12), have been related with cognitive 
dysfunction in many observational study (Riedel et al., 1998). In some studies, 
pathophysiological models have been formulated, including the association of B vitamin 
deficiencies with metabolic disturbances in the structural constituents of cerebral tissue, 
such as phospholipids and myelin, as well as in signaling molecules, such as 
neurotransmitters (Rampersaud et al., 2003). In particular, thiamine deficiency has been 
associated with lactic acid accumulation, reduction in oxygen uptake, decrease in 
transketolase activity, and an impairment in cholinergic activity, leading to the loss of 
memory and other cognitive functions (Micheau et al., 1985). Cobalamin is essential for 
neuronal generation and its deficiency can cause degeneration of the nervous system 
(Herrmann & Obeid, 2007). Various cobalamines were shown to have intracellular 
antioxidant activity in vitro. The compounds inhibited intracellular peroxide production, 
maintained intracellular glutathione levels, and prevented apoptotic and necrotic cell death 
(Birch et al., 2009). Folic acid plays an important role in neuroplasticity and in the 
maintenance of neuronal integrity (Kronenberg et al., 2009). It enhances the plasma 
concentrations of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). EPA, 
DHA, and arachidonic acid are of benefit in dementia by up-regulating gene expression 
concerned with neurogenesis, neurotransmission and connectivity, improving endothelial 
nitric oxide (eNO) generation, enhancing brain acetylcholine levels, suppressing the 
production of proinflammatory cytokines and precursing to anti-inflammatory compounds 
that protect neurons from cytotoxic action of various noxious stimuli, oxidative stress and 
neuronal apoptosis (Das, 2008). 
Recently, the association between the deficiency of B vitamins, particularly folate and 
cobalamin, and cognitive impairment has been investigated in relation to 
hyperhomocysteinemia (hHcy). Several epidemiological studies have also suggested that 
hHcy may play a role in the cognitive performance (Prins ND, 2002) and pathophysiology of 
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dementia in older people (Bell et al, 1992; Nilsson et al., 1996; Wahlin et al., 1996), possibly 
as the metabolic link between micro-vascular disease and old-age dementia (M.S. Morris et 
al., 2001; Parnetti et al., 1997). Feeding mice with a B-vitamin deficient diet for 10 weeks 
induced hHcy, significantly impaired learning and memory, and caused a significant 
rarefaction of hippocampal microvasculature unrelated to gliosis and neurodegeneration 
(Troen et al., 2008). 
Homocystein (Hcy) is an aminoacid entirely derived from the body’s intermediary 
metabolism (Fekkes et al., 1998; Pietrzik & Bronstrup, 1997), which can be converted to 
either methionine or cysteine. Both folate and cobalamin participate in the methylation of 
Hcy to methionine and in the remethylation and synthesis of S-adenosylmethionine 
(Bottiglieri, 1996; Parnetti et al., 1997). The other metabolic pathway, which converts Hcy to 
cysteine requires the active form of vitamin B6 (pyridoxal phosphate) (Pietrzik & Bronstrup, 
1997). The most common cause of hHcy is accepted to be a deficiency of folate or cobalamin 
(Selhub, 2000). Almost two-thirds of the prevalance of hHcy is attributable to low vitamin B 
status or intake (Selhub J, 2008). Although the catabolic rate of Hcy results from the 
interaction between genetic make-up and B vitamin status, it is generally accepted that 
elevated plasma Hcy concentrations are a sensitive marker for folate and cobalamin tissue 
deficiency (Bottiglieri, 1996; Joosten et al., 1993; Lokk, 2003; McCaddon et al., 1998; Nilsson 
et al., 1996; Nilsson et al., 1999; Parnetti et al., 1997).  
Folate and vitamin B12 are essential cofactors for the methionine/Hcy cycle in the brain. 
These vitamins mediate the remethylation of Hcy, which affects the production of the 
universal methyl donor, S-adenosylmethionine, in the brain among other organs. 
Hypomethylation, caused by low B-vitamin and hHcy, is linked to key pathomechanisms of 
dementia (Obeid et al., 2007). Also, Hcy is recognised to be proatherogenic and protrombotic 
(Hassan et al., 2004) and accepted to be an independent risk for developing occlusive arterial 
diseases (Refsum et al., 1998; Ueland & Refsum, 1989). hHcy exerts an inhibitory effect on 
adult mouse brain neurogenesis (Rabaneda et al., 2008).  Low folate status and elevated Hcy 
increase the generation of reactive oxygen species and contribute to excitotoxicity and 
mitochondrial dysfunction which may lead to apoptosis (Kronenberg et al., 2009). hHcy is 
also proposed to be one of the effects of the oxidation of vitamin B12, as a result of oxidative 
stress (McCaddon et al., 2002). Furthermore, experimental studies in cell cultures have 
shown that Hcy is neurotoxic, possibly by activating N-methyl-D-aspartate receptors 
(Lipton et al., 1997) or DNA damage and consequent apoptosis (Kruman et al., 2000). In a 
population based study on 1779 subjects, hHcy has been reported to be an independent risk 
factor for dementia and cognitive impairment without dementia (Haan et al., 2007). 
Depending on the used marker, 3-60 % of the elderly are classified as vitamin B12 deficient 
and about 29 % as folate deficient. Predominantly, the high prevalance of poor cobalamin 
status is caused by the increasing prevalance of atrophic gastritis type B, which occurs with 
a frequency of approximately 20-50% in elderly subjects (Wolters et al., 2004). Another cause 
of atropfic gastritis is  long term treatment with proton pump inhibitors (Kuipers et al., 
1995,1996; Lundell et al., 2006).   Atrophic gastritis results in declining gastric acid and 
pepsinogen secretion, and hence decreasing intestinal digestion and absorption of both B 
vitamins. Such patients with atrophic gastritis require parenteral supplements. Folic acid 
intake among elderly subjects is generally well below the recommended dietary reference 
values (Wolters et al., 2004). So, folic acid deficiency is primarily caused by dietary 
deficiency. Meanwhile, vitamin B12 deficiency is due to two main causes, food cobalamin 
malabsorption and pernicious anemia (Andres et al., 2004).  
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3.2 Studies 
Many epidemiological, cross-sectional and case control studies reported the association of 
dementia with low blood levels of vitamin B12 and folate or hHcy. Hovewer, these studies 
are unable to exclude the possibility that such associations of hHcy or vitamin B deficiencies 
are rather a result than a cause of the disease.  
Kivipelto  M et al (Kivipelto et al., 2009), in their prospective study found that persons with 
high Hcy had more than twice as high a risk of developing AD than persons with low Hcy, 
even after adjusting for confounding or mediating factors, suggesting that Hcy is involved 
in the development of dementia and AD. Vitamin B12 itself seemed not to be directly 
involved, because holo-transcobalamin showed no association with dementia. In  some 
cohort studies, hHcy  was found to be correlated with decline in constructional praxis and 
recall memory (Tucker et al., 2005) and increased risk for dementia (Dufoil et al., 2003; Haan 
et al., 2007; Ravaglia et al., 2005; Seshadri et al., 2002; McCaddon et al., 2001), while in some 
others it was not correlated with cognitive decline  (Clarke et al., 2007; Kalmijn et al., 1999; 
Luchsinger et al., 2004; Mooijaart et al., 2005; Teunissen et al., 2003). In the cohort studies, 
low plasma level of folate was found to be associated with decline in constructional praxis 
and lower cognitive function regardless of Hcy respectively (de Lau et al., 2007; Tucker et 
al., 2005). In another cohort study performed on 370 non demented persons older than 74 
years of age, persons with low serum level of vitamin B12 or folate had the risk of 
developing AD (Wang et al., 2001). In addition to low folate and high Hcy plasma levels, 
low plasma concentration of vitamin B12 was also associated with decline of constructional 
praxis in a 3 year cohort study (Tucker et al., 2005).  
Cohort studies of dietary intake of B vitamins in healthy elderly persons revealed conflicting 
results. In one of them, dietary intake was found to be not related with the risk of 
developing AD (MC Morris, 2006a). In another, the highest quartile of total folate intake was 
related to lower risk of AD (Luchsinger et al., 2007), while the other reported that rate of 
cognitive decline among persons in the top folate intake was more than twice that of those 
in the lowest fifth of intake (MC Morris et al., 2005b).  
Despite potential benefits of vitamin B supplementation for lowering Hcy, the positive 
contribution of this supplementation to cognitive function among demented and non-
demented persons remains debatable. There was a large heterogeneity among present 
vitamin B interventional studies with cognitive assessments in terms of dosage, routes of 
intervention (for vitamin B12), age and cognitive function assessments. 
It has been proven that folate supplementation reduces plasma Hcy levels. This was 
observed by Jacques et al. in the Framingham Offspring Study cohort, after the folate 
fortification of grain in the Unites States started in January 1998 (Jacques et al., 1999). 
Nevertheless, the relationship between dietary folic acid intakes and plasma Hcy 
concentrations seems to be characterized by a threshold effect (Selhub, 1993): above a certain 
dosage of folate supplementation, there is no additional effect on lowering circulating Hcy. 
It is not clear where this threshold stands: a metanalysis of 12 randomized controlled trials 
assessed that the minimum dosage of folate capable of determining a maximum reduction 
(about %25) of circulating Hcy was 0.5 mg/day. More recent randomized trials determined 
this threshold at 0.8 mg/day (Wald et al., 2001) or 0.4 mg/day (van Oort et al., 2003). The 
differences are possibly explained by population selection biases (van Oort et al., 2003). 
Some randomised controlled trials, including persons with normal cognitive function, 
cognitive impairment and dementia, evaluated the effect of folate supplementation on 
cognitive function. Among cognitively impaired subjects (n=30) with low folate serum 
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levels, Fioravanti et al (Fioravanti et al., 1998) observed a significant improvement of some 
scores of the Randt Memory Test in the folate treated group compared with the placebo 
group after 60 days of treatment. In another trial using a mixed factorial design in normal 
subjects (n=211), the authors observed that folate-treated older women’s cognitive test 
scores (Rey Auditory-Verbal Learning Test) improved (Bryan et al., 2002). Controversially, 
in another small study including 7 subjects with dementia reported no statistically 
significant differences between the supplemented group and the control group, and noted a 
negative trend in specific test scores of the supplemented group (Sommer et al., 2003). 
Because of the small number of subjects, study results need to be interpreted cautiously. 
Finally, the 3-year randomised controlled FACIT trial included 818 older subjects (older 
than 60 years) with augmented plasma total Hcy and normal serum vitamin B12 levels. The 
effect of folic acid supplementation on cognition was the secondary end point. The 3-year 
change in memory, information processing speed and sensorimotor speed were significantly 
improved in the folic acid group in comparison to the placebo group (Durga et al., 2007). 
Folic acid potentiated the effect of memantine on spatial learning and neuronal protection in 
an AD transgenic model (Chen et al., 2010). 
Some other randomised controlled studies assessed the effect of vitamin B12 intervention on 
cognitive functions in humans. There is a large heterogeneity among trials regarding the 
cognitive status of participants, the doses and administration routes of vitamin B12, the 
duration of supplementation and the applied cognitive function assessment instruments. 
Sample sizes ranged from 18 to 78 subjects receiving vitamin B12, and the duration of 
supplementation ranged from 4 weeks to 6 months. For most cognitive tests, there was no 
significant improvement in vitamin B12 supplemented patients as compared with the placebo 
group (Eussen et al., 2006; Hvas et al., 2004; Stoot et al., 2008). However, Bryan J et al found 
that healthy younger, middle-aged and older women (n=211) who took vitamin B12 (or either 
of folate and vitamin B6 ) for 35 days showed better performance on some measures of 
memory performance compared to placebo (Bryan et al., 2002). Interestingly, a statistically 
significant worsening of cognitive tests was reported in two studies. In 195 vitamin B12 
deficient subjects of normal and impaired cognition, Eussen et al (Eussen et al., 2006) observed 
that improvement of the cognitive test score in the placebo group was significantly more 
marked than that of the vitamin B12 group. Similarly, another study reported a significant 
worsening of the ‘12 words learning test’ score in a vitamin B12 treated population of 140 old 
patients with cognitive impairment and methylmalonic acidemia, in comparison to the 
placebo group (Hvas et al., 2004). For reasons of heterogeneity of these controlled trials, no 
reasonable conclusion can be drawn regarding the effects of vitamin B12 on cognition. In 
addition, several uncontrolled cohort studies assessed the effects of vitamin B12 intervention 
on cognitive function in humans with conflicting results.  
A few studies (Lewerin et al., 2005; McMahon et al., 2006; Stott et al., 2005; van Uffelen et al., 
2007) reported data of combined B vitamin intervention on cognition, in subjects with 
normal cognition, dementia or vascular disease (17-409 participants). Trial durations ranged 
from 12 weeks to 2 years. One study found a significant improvement in one of eight 
cognitive tests (Reitan trail-making test, part B) (McMahon et al., 2006). In a recent 
randomized, double-blind controlled study in 271 individuals over 70 years old with mild 
cognitive deficit,  high dose B vitamins lowering Hcy level slowed the rate of accelerated 
brain atrophy, which was found to be major determinant of cognitive decline in this 
population (Smith et al., 2010). It was reported that trials were needed to see if the same 
treatment will delay the development of AD (Smith et al., 2010). 
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3.3 Comments 
Most studies reporting associations between cognitive function and Hcy or B vitamins have 
used a cross-sectional or case-control design and have been unable to exclude the possibility 
that such associations are a result of the disease rather than being causal. The prospective 
study indicating that persons with high Hcy have more than twice as high as developing 
AD than persons with low Hcy, even after adjusting for confounding or mediating factors, is 
an important one. The Hcy hypothesis of dementia has attracted considerable interest, as 
Hcy can be easily lowered by folic acid and vitamin B12, raising the prospect that B-vitamin 
supplementation could lower the risk of dementia (Clarke et al., 2008). While some trials 
assessing effects on cognitive function have used folic acid alone, vitamin B12 alone or a 
combination, few trials have included a sufficient number of participants to provide reliable 
evidence. Among these studies, FACIT Trial  (Durga et al., 2007) is an outstanding one. This 
large, randomised and controlled trial on elderly participants with high plasma Hcy and 
normal vitamin B12 serum level have showed that folic acid supplementation improved 
several cognitive domains that tend to decline with advancing age. Therefore, folate 
supplementation may be an interesting approach to prevent cognitive decline in elderly 
people.  New trials with larger number of participants are needed to test the importance of 
vitamin B intake through diet or supplementation forms in the prevention and treatment of 
AD.   
4. Vitamin D 
Vitamin D exhibits functional attributes that may prove neuroprotective through 
antioxidative mechanisms, neuronal calcium regulation, immunomodulation, enhanced 
nerve conduction and detoxification mechanisms. Compelling evidence supports a 
beneficial role for the active form of vitamin D in developing brain as well as in adult brain 
function. The vitamin D receptor and, biosynthetic and degredative pathways for the 
hydroxylation of vitamin D have been found in the rodent brain; more recently these 
findings have been confirmed in humans. The vitamin D receptor and catalytic enzymes are 
colocalized in the areas of the brain involved in complex planning, processing, and the 
formation of new memories. These findings potentially implicate vitamin D in 
neurocognitive function (Buell & Dawson-Hughes, 2008). 
Treatment with 1,25 (OH)2D3 attenuated hippocampal atrophy and protected neuron 
density ( a marker for neuronal death) in aging rats (Landfield & Cadwalleder-Neal, 1998). 
Data in human subjects  with AD revealed a reduction in VDR mRNA in specific regions of 
the hippocampus (CA1 and CA2) compared to controls (Sutherland et al., 1992) and a higher 
frequency of VDR polymorphisms were found in Alzheimer’s brains than age-matched 
controls (Gezen-Ak et al., 2007).  
Low serum levels of 25(OH)D have been associated with increased risk for cardiovascular 
diseases, diabetes mellitus, depression, dental caries, osteoporosis, and periodontal disease, all 
of which are either considered risk factors for dementia or have preceded incidence of 
dementia. There is a higher prevalence of falls and fractures in patients with AD (Buchner & 
Larson, 1987) and community studies have shown that residents with AD and dementia had 
lower serum concentrations of 25(OH)D (Kipen et al., 1995). While the temporal associations of 
these findings remains unclear, in a study in patients with AD, 25(OH)D concentrations were 
significantly elevated after year-round sun exposure. Additionally, the sun- exposed cohort 
had a reduced risk of falls and fractures compared to the unexposed  (Sato et al., 2005).  
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Data from the Nutrition and Memory in Elderly study (NAME) (Scott et al., 2004) supported 
these findings. In subjects (n=318) who completed a full neurological and psychiatric 
examination, in addition to magnetic resonance imaging, it was observed that vitamin D 
concentrations were lower in patients with dementia than those without. Additionally, 
vitamin D concentrations lesser than 50 nmol/L were associated with a higher prevalence of 
a diagnosis of possible or probable AD. In a recent cross-sectional investigation of vitamin 
D, dementia and MRI measures of cerebrovascular disease among 318 participants, mean 
vitamin D concentrations were lower in subjects with dementia. There was a higher 
prevalence of dementia, large vessel infarcts and increased white matter hyperintensity 
volume among participants with vitamin D insufficiency. After adjustment for age, race, sex, 
bodymass index, and education, vitamin D insufficiency was associated with more than 
twice the odds of all cause dementia, AD and stroke (Buell et al., 2010). Based on increasing 
number of studies linking the risk factors of AD with vitamin D deficiency, Grant WB 
(Grant, 2009) states that there are established criteria for causality in a biological system. The 
important criteria include strength of association, consistency of findings, determination of 
the dose-response relation, an understanding of the mechanisms, and experimental 
verification. Grant WB  (Grant, 2009) suggests that further investigation of possible direct or 
indirect linkages between vitamin D and dementia is needed.  Studies of incidence of 
dementia with respect to prediagnostic serum 25(OH)D or of vitamin D supplementation 
are warranted. In addition, since the elderly are generally vitamin D deficient and since 
vitamin D has so many health benefits, those over the age of 60 years should consider 
having their serum 25(OH)D tested, looking for a level of at least 30 ng/ml but preferably 
over 40 ng/ml, and supplementing with 1000-2000 IU/day of vitamin D3 or increased time 
in the sun spring, summer, and fall if below those values (Grant, 2009). 
5. Vitamin K 
Vitamin K is necessary for the liver functioning. Vitamin K dependent Ǆ-carboxylation of 
glutamate takes part in formation of the coagulation factors 2, 7, 9 and 10. More recently, it 
has been established that vitamin K dependent Ǆ-carboxylation of glutamate occurs also in 
extrahepatic sites and modifies proteins with other functions. One of these sites is brain. 
Allison AC (Allison, 2001) proposed a possible role of vitamin K deficiency in the 
pathogenesis of AD and in augmenting brain damage associated with cerebrovascular 
disease, based on the potential actions of vitamin K in the brain and through a link to the 
apolipoprotein E genotype. The apolipoprotein E4 allele, an established risk factor for AD 
(Mattson, 2004), strongly influences plasma vitamin K levels (Kohlmeier M, 1996; Saupe J, 
1993). Thus, carriers of apolipoprotein E4 allele could also those with the lowest vitamin K 
concentrations, an association that has not yet been investigated. Vitamin K is required for 
normal brain development and function. The maternal exposure to coumarin derivatives is 
associated with abnormalities of the central nervous system (Pauli & Haun, 1979). Vitamin K 
deficiency is associated with decrased sulfation in the brain. Keratan sulfate is dramatically 
decreased in cerebral cortex of AD patients (Lindahl, 1996). Considering keratan sulfate 
proteoglycan being the major protein of synaptic vesicles (Scranton et al., 1993), one 
manifestation of decreased sulfation can be abnormal structure and function of the major 
protein of synaptic vesicles (Allison, 2001). Likewise, addition of vitamin K to the chick 
embriyo increases tyrosine phosphorylation in the brain adhesion and cytoskletal proteins 
(Saxena et al., 1997), suggesting that vitamin K plays an role in the development of the 
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central nervous system. Another vitamin K dependent protein in the brain is Gas 6, a 
product of growth arrest specific gene 6. Both Gas 6 and its tyrosine kinase receptor are 
widely distributed throughout the central nervous system (Prieto et al., 1999). Interaction of 
these plays an important role in preventing neurons from apoptosis (Allen et al., 1999). Cell 
culture studies have shown that Gas 6 can rescue cortical neurons from Aǃ induced 
apoptosis (Yagami et al., 2002) and provided evidence that vitamin K can have a protective 
role against oxidative injury in developing oligodendrocytes and neurons (Denisova & 
Booth, 2005). 
Considering that a relative deficiency of vitamin K, affecting the extrahepatic functions of 
the vitamin, is common in aging men and women; Allison AC (Allison, 2001) suggests that it 
is obviously useful to do experimental animal and case controlled human studies in the first 
step to clarify the role of vitamin K in the pathogenesis of dementia. In a likely study, low 
vitamin K intakes in 31 community-dwelling elders at an early stage of AD was detected  in 
comparison to 31 age and sex matched cognitively intact control subjects (Presse et al., 2008). 
6. Multi-intervention 
Due to the fact that the interventional trials with antioxidants and B-vitamins did not hold 
the expectations, studies combining micronutriens are of particular interest. To date, a few 
prospective studies estimating the effect of nutrition and vitamin supplementation exist. 
One of these studies (Wolters et al., 2005) was performed on 220 healthy, free living women 
older than 60 years of age. After taking multivitamins (containing 8 vitamins and 4 
minerals) for 6 months daily, no change on cognitive performance was observed as 
compared to placebo. The intervention period of only 6 months may be too short for 
improving cognitive performance in well-educated elderly women without dementia.  
Another study (McNeill et al., 2007) was performed on 910 healthy men and women aged 65 
years and over. Four hundred and fifty six of them were on active daily treatment with 11 
vitamins and 5 minerals for 12 months, while the remaining ones took placebo. Benefit was 
detected only on verbal fluency tests in the subgroups of participants aged over 74 years or 
those with increased risk of micronutrient deficiency. In a 12 month, open label trial with 14 
mild AD patients, the efficacy of a multi-component formulation showed promising results 
regarding neuropsychiatric inventory and activities of daily living (Chan et al., 2008). This 
was confirmed by placebo-controlled data from 12 institutionalized patients with moderate 
to severe AD showing improvement in cognition, mood, and daily function (Remington et 
al., 2009). As a result, to draw any conclusion, larger randomized controlled studies with 
combined supplements are needed, especially in the context that multi-component dietary 
approaches such as Mediterranean diet or fruit and vegetable (or juice) consumption have 
been shown to be successful (Barberger-Gateau et al, 2007; Dai et al., 2006; MC Morris et al., 
2006b; Scarmeas et al., 2006, 2009). 
7. Conclusion 
There is a relationship of levels of antioxidant vitamins and B vitamins to vascular 
dementia. Nevertheless, if this relationship is based on causality, it is not so clear after 
performed longitudinal and interventional studies. New trials with larger number of 
participants will be more clarifying. Recently, vitamin D deficiency has been found to be 
related with AD.  Longitudinal and interventional studies, especially with long follow up 
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period, will be informative about its role. Additionally, vitamin K is thought to have a 
possible role in the pathogenesis of dementia. 
The subject has multiple aspects. As vitamin deficiencies can cause cognitive impairment, 
cognitive impairment can also determine changes in dietary habits and consequently cause 
vitamin deficiencies. Vitamin intake through diet or supplementation forms can have 
different effects. There is also a possibility that vitamins have useful effects in different 
subgroups of people, based on age, nutritional status or vitamin level.  Multivitamin 
supplementation may be more useful. The roles of vitamins in dementia are not clear yet as 
those of macronutrients in spite of the reports expressing the benefits of caloric restriction 
and intake of higher unsaturated fatty acids on cognitive functions. Presence of relationships 
between macronutrients and vitamins is also possible. Detailed investigations about these 
aspects will be informative. 
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